Medicus Pharma advances D-MNA with FDA engagement, strong Phase 2 progress, and solid balance sheet

Proactive - Interviews for investors

Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

14d ago 6:02

MP3•Episode home

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to share a series of important corporate and clinical updates, including regulatory progress with the U.S. Food and Drug Administration (FDA), advancement of its Phase 2 study, and a strengthened financial position. Bokhari explained that the FDA has accepted the Company’s Type C meeting request, which provides an opportunity for Medicus to engage directly with the agency on the development pathway for its novel D-MNA (SKNJCT-003) technology. The company has formally submitted its queries in writing and expects to receive a response from the FDA before the end of Q3 2025. The purpose of the Type C meeting is to gain further alignment with the FDA on the clinical development strategy, including the potential to fast-track the program. Bokhari emphasized that this interaction is critical for advancing Medicus Pharma’s vision of bringing its non-invasive therapy for basal cell carcinoma (BCC) closer to patients. Meanwhile, the Company’s Phase 2 clinical trial evaluating the novel D-MNA approach for treating BCC continues to make strong progress. More than 75% of the planned 90 patients have now been randomized into the study, keeping the program on track to achieve enrollment targets. In addition to regulatory and clinical milestones, Medicus reported Q2 2025 financial results that highlight a substantially improved balance sheet. The Company added $11.5 million in aggregate net proceeds from financing transactions and warrant exercises during the quarter. As a result, cash and cash equivalents grew to $9.7 million at the end of Q2, up significantly from $4.0 million at the end of Q1 2025. This financial strength supports the continued advancement of its clinical pipeline, pursuit of strategic transactions, and the ongoing buildout of its core management team. Bokhari noted that the combination of regulatory momentum, clinical trial progress, and financial flexibility positions Medicus Pharma to accelerate the development of its innovative D-MNA platform and advance toward potential future commercialization opportunities. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation

610 episodes

#Trading #Business News #Business #News #Proactive Investors #Gold #Cannabis #Battery Metals #Chief Executive #Biotech #Natural Resources #Bitcoin #Cryptocurrency #Interviews #Investing #Investment Research #Mining #Retail Investment #Technology